Table 3.
Incidence of TiPN, BiPN, and lenalidomide-induced PN: summary of phase II and phase III studies*
*For thalidomide in relapsed MM, pooled data from the meta-analysis are shown. All other selected studies are pivotal with detailed PN reporting; †median dose of thalidomide 50–200 mg/d; ‡median dose of thalidomide > 200 mg/d; §http://www.emea.europa.eu/humandocs/PDFs/EPAR/revlimid/H-717-en6.pdf; ¶maximum thalidomide dose 400 mg; #maximum thalidomide dose 100 mg. (Adapted from Delforge et al., in press.9 )
NR, not reported; dex, dexamethasone; len, lenalidomide; thal, thalidomide; MP, melphalan/prednisone; MPT, melphalan/prednisone/thalidomide; VMP, bortezomib/melphalan/prednisone; VAD, vincristine/doxorubicin/dexamethasone
